cGMP Method Development & Validation
Build, optimize, and validate analytical procedures for regulated pharmaceutical materials, complex matrices, and solid-state questions.
Release testing depends on method status, specifications, and defensible records
Release testing is not method development with a certificate attached. A cGMP release decision depends on a defined method, defined specification, representative sample, suitable controls, traceable data, laboratory records, and a reporting package that can be reviewed by quality, regulators, clients, and sponsors.
Triclinic supports release testing when the method, matrix, specification, quality agreement, sample status, and documentation path are appropriate for regulated execution. Where those pieces are not yet ready, the work should first be routed through method development, verification, validation, or transfer.
When cGMP release testing is the right starting point
- A client has an approved, verified, validated, or transferable method and a defined specification.
- A batch, lot, raw material, intermediate, excipient, drug substance, drug product, stability sample, or filing-support sample requires regulated testing.
- The project requires a certificate/reporting package, QA-reviewable records, chain of custody, and controlled data handling.
- A compendial or established procedure must be executed for identity, assay, impurities, water, particle size, thermal behavior, morphology, spectroscopy, XRPD, NMR, or other agreed attributes.
- The sponsor needs a release-testing laboratory path that is technically aligned with solid-state and complex-matrix behavior.
How Triclinic approaches cGMP release testing
Before samples are accepted for release testing, the method package, specifications, acceptance criteria, sample requirements, reference standards, quality agreement, and reporting expectations should be clear. Triclinic reviews whether the work is truly ready for release execution or whether method verification, transfer, adaptation, or validation is needed first.
Execution focuses on controlled sample receipt, chain of custody, method adherence, system suitability, standards and controls, instrument readiness, calculations, data review, and documentation of any deviations or unexpected results. The scientific review does not stop at pass/fail; for complex materials, the data package should also be coherent with the matrix and method limitations.
For solid-state release questions, Triclinic emphasizes technique selection and controls that reflect the attribute being released: polymorphic form, crystalline content, amorphous content, water, particle size, morphology, identity, impurity, or quantitative phase content.
Regulatory and quality framework reflected in the work
Regulated method work should be scoped to the intended use of the procedure, the sample matrix, the decision the data must support, and the quality-system status of the work. For cGMP work, laboratory controls, specifications, sampling, testing, release decisions, and laboratory records must be planned so that the resulting data package can be reviewed, repeated, and defended.
- Under 21 CFR 211.165, batch release decisions require appropriate laboratory determination of conformance to final specifications before release.
- Under 21 CFR 211.160, laboratory controls must include scientifically sound specifications, standards, sampling plans, and testing procedures.
- Under 21 CFR 211.194, laboratory records must include complete data derived from tests, examinations, and assays necessary to assure compliance with established specifications and standards.
- FDA data-integrity expectations should be reflected in how data are generated, reviewed, retained, corrected, and reported.
- If a method is not yet suitable for cGMP release testing, route the work to development, verification, validation, or transfer before treating results as release data.
Typical deliverables
- Project intake summary covering method, specification, sample, lot/batch, storage, handling, and reporting requirements.
- Controlled execution records, raw data, instrument output, calculations, chromatograms, spectra, diffractograms, images, or other primary data as applicable.
- System suitability, standards, controls, and acceptance-criteria documentation.
- cGMP report or certificate/reporting package suitable for the agreed release or quality decision.
- Deviation, OOS, OOT, or investigation support when triggered under the applicable quality process.
- Recommendations where method status, sample condition, specification, or data behavior indicates that additional development or validation is needed.
Figures and Examples
Related services and capabilities
cGMP Release Testing
Execute approved, verified, or transferred methods against defined specifications for batch, lot, raw material, stability, or filing-support decisions.
cGMP Method Transfer
Move a method between laboratories, instruments, matrices, or quality systems without losing the scientific basis for equivalence.
cGMP Analytical Services
Connect method work to regulated XRPD, spectroscopy, NMR, particle, morphology, thermal, compendial, and release-testing services.
Analytical Capabilities Hub
Review the instruments and techniques that may be used to develop, validate, verify, transfer, or execute the method.
Common questions
Can Triclinic issue a CoA or release-testing report?
Where the method, specification, sample, quality agreement, and documentation path support it, Triclinic can provide a release-testing reporting package appropriate to the agreed scope. The exact report type should be defined before samples are submitted.
Can release testing begin if the method has not been validated or transferred?
It should not be treated as routine cGMP release testing until method status is clear. If the method is not ready, the correct path is usually verification, validation, method transfer, feasibility, or development first.
What is needed to start release testing?
Provide the method, specification, acceptance criteria, sample identity, batch or lot information, storage and handling requirements, reference standards, prior data if relevant, quality agreement expectations, reporting requirements, and timeline.
What happens if results are unexpected?
Unexpected results should be handled according to the applicable quality process, which may include data review, instrument and sample checks, deviation documentation, OOS/OOT procedures, investigation support, or client-directed follow-up testing.
Can release testing use solid-state methods?
Yes, if the method is appropriate and controlled for the release attribute. XRPD, Raman, FTIR, NMR, microscopy, particle size, thermal analysis, water determination, and other methods may be relevant depending on the specification.
Do you develop, validate, and transfer methods?
Yes. Triclinic develops, validates, verifies, and transfers methods that support cGMP release testing when the existing method, matrix, specification, or sample behavior requires additional method work. The goal is to align the procedure, system suitability, acceptance criteria, documentation, and reporting package with the release or stability decision.
Who makes the final batch-disposition decision?
The manufacturer or authorized quality unit makes the final batch-disposition decision. The testing laboratory provides controlled analytical results and the agreed reporting package within its defined responsibility.
Discuss cGMP release testing requirements
Send the method, specification, sample type, lot or batch information, reference-standard needs, reporting requirements, quality-agreement status, and whether the work supports release, stability, filing, or investigation support.
